Australian company Island Pharma (ASX:ILA) has announced that it has been granted an Australian patent for its drug ISLA-101. The patent is valid until April 16, 2034. The patent covers methods of treating or preventing yellow fever and other mosquito-borne viral infections through the use of ISLA-101.
Island Pharma said the patent supports the company’s drug repurposing strategy to rapidly develop antiviral therapeutics, with a focus on mosquito-borne viral diseases such as dengue. Prevention of dengue fever, which infects approximately 390 million people each year, represents a significant unmet need and opportunity for the disease.
This new patent adds to the growing intellectual property barriers surrounding ISLA-101.
Dr. David Foster, Chief Executive Officer of Island Pharma, said, “This Australian patent, along with equivalent patents granted in other major markets, supports our investment in advancing ISLA-101 as a potential new approach to combat the growing global epidemic of dengue and other mosquito-borne viral diseases.”
This latest Australian patent further strengthens Island Pharma’s strong IP portfolio, which also includes patents in the US, Canada, Brazil and Singapore.
The market appeared to have a muted reaction to the news. As of 2 p.m. (AEDT), ILA’s shares were up a modest 1.43 percent on the day.
Chimeric Therapeutics’ CHM 1101 CAR T-cell therapy administered for the first time in a Phase IB clinical trial in patients with recurrent and/or progressive glioblastoma multiforme (GBM)
Cell therapy company Chimeric Therapeutics (ASX: CHM) said it has completed the first administration of its Phase B clinical trial in patients with recurrent and/or progressive glioblastoma multiforme (GBM), who received CHM 1101 CAR T cell therapy.
The patient was treated at the Sarah Cannon Transplantation and Cell Therapy Program at St. David’s South Austin Medical Center in Austin, Texas, USA. The patient received CHM 1101 as second-line therapy.
The Phase I B clinical trial of CHM 1101 was conducted under an FDA IND (Investigational New Drug) application and was designed as a two-part clinical trial (Part A, Dose Confirmation; Part B, Dose Expansion).
Following the successful completion of the Part B dose expansion cohort trial, Chimeric will work with global regulators to design and initiate a registration trial.
We believe that the full potential of CHM 1101 for the treatment of patients with recurrent or progressive glioblastoma can only be realized by advancing our clinical development program, and we look forward to continuing to move this trial forward,” said Jennifer Chow, Chief Executive Officer of Chimeric.
As of 2 p.m. (AEDT), Chimeric’s shares were up nearly 3.5 percent on the day.
![](https://footwearjourney.com/wp-content/uploads/2023/11/image-1.png)
Imugene passes VAXINA trial milestone
Meanwhile, Imugene (ASX: IMU) announced that it has passed certain milestones in its MAST (Metastatic Advanced Solid Tumor) Phase I trial evaluating the novel oncolytic virus CF33-hNIS (VAXINIA).
The study passed Group 4 of the single-agent IV dose-escalation study IV treatment arm and Group 2 of the VAXINIA in combination with the blockbuster drug pembrolizumab (KEYTRUDA) study IV treatment arm.
Cohort 5 of the single-agent IV dose-escalation study and Cohort 3 of the IV dose-escalation study of the combination therapy study are now open.
Leslie Chong, chief executive officer of Imugene, said the company now has the opportunity to expand the trial to enroll additional cohorts of patients in the single-agent dose-escalation portion.
“This will provide us with a more robust dataset to analyze and discuss at the end of the MAST study and a stronger platform for us to further advance the clinical development of CF33 and VAXINIA. She said.